Skip to main content
NCBI home page
Journal of Cancer Research and Clinical Oncology logoLink to Journal of Cancer Research and Clinical Oncology
. 1990 Jan;116(1):21–23. doi: 10.1007/BF01612635

Combination chemotherapy of advanced medullary and differentiated thyroid cancer

Phase II study

Hans Scherübl 1, Friedhelm Raue 1,✉, Reinhard Ziegler 1
PMCID: PMC12201629  PMID: 2312602

Abstract

A group of 20 patients with advanced medullary (MTC) or differentiated thyroid carcinoma (DTC) received a combination chemotherapy of doxorubicin (50 mg/m2), cisplatin (60 mg/m2) and vindesine (3 mg/m2). In the 18 (10 MTC, 8 DTC) evaluable patients only 1 partial remission (in a patient with MTC) and 3 minor responses (in 3 patients with DTC) were observed. These responses lasted for 15, 9, 13, and 22 months, respectively. Three MTC patients suffered from progressive disease and “no change” was seen in the other 11 patients. Toxicity, including 1 severe case of cardiomyopathy, was considerable. Thus, the combination chemotherapy of doxorubicin, cisplatin and vindesine has failed to prove superior to the commonly applied doxorubicin monotherapy in patients with advanced medullary or differentiated thyroid carcinoma.

Key words: Thyroid cancer, Chemotherapy, Doxorubicin, Cisplatin, Vindesine

Abbreviations

MTC, DTC

medullary and differentiated thyroid carcinoma

Footnotes

This study was supported by a grant of the German Cancer Research Center (Tumorzentrum Heidelberg/Mannheim)

References

  1. Ahuja S, Ernst H (1987) Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10:303–310 [DOI] [PubMed] [Google Scholar]
  2. Athanassiades P, Piperingos G, Pandos P, Koutras D, Moulopoulos S (1988) Serial serum calcitonin concentrations to evaluate response to therapy of patients with medullary thyroid carcinoma. Chemioterapia 7:195–197 [PubMed] [Google Scholar]
  3. Benker G, Reinwein D (1983) Ergebnisse der Chemotherapie des Schilddrüsenkarzinoms. Dtsch Med Wochenschr 108:403–406 [DOI] [PubMed] [Google Scholar]
  4. Bukowski RM, Brown L, Weick JK (1983) Combination chemotherapy of metastatic thyroid cancer. Phase II study. Am J Clin Oncol (CCT) 6:579–581 [PubMed] [Google Scholar]
  5. Droz JP, Schlumberger M, Rougier P, Caillou B, Godefroy W, Gardet P, Parmentier C (1985) Phase II trials of chemotherapy with adriamycin, cisplatin and their combination in thyroid cancers — a review of 44 cases. In: Jaffiol C, Milhaud G (eds) Thyroid cancer. Elsevier Science Publishers, Amsterdam, pp 203–208 [Google Scholar]
  6. Gottlieb JA, Hill CS Jr (1974) Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. N Engl J Med 290:193–197 [DOI] [PubMed] [Google Scholar]
  7. Hedinger C, Williams ED, Sobin LH (1988) Histological typing of thyroid tumours, 2nd edn (International histological classification of tumours No. 11). Springer, Berlin Heidelberg New York [Google Scholar]
  8. Miller AB, Hoogstraten B, Staquet M, Winkler A (1981) Reporting results of cancer treatment. Cancer 47:207–214 [DOI] [PubMed] [Google Scholar]
  9. Petursson SR (1988) Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with decarbazine and 5-fluorouracil. Cancer 62:1899–1903 [DOI] [PubMed] [Google Scholar]
  10. Poster DS, Bruno S, Penta J, Pina K, Catane R (1981) Current status of chemotherapy in the treatment of advanced carcinoma of the thyroid gland. Cancer Clin Trials 4:301–307 [PubMed] [Google Scholar]
  11. Raue F, Minne H, Ziegler R (1985) Cisplatin, Adriamycin und Vindesin: Eine Kombinationschemotherapie beim differenzierten Schilddrüsenkarzinom. Tumor, Diagn Ther 6:134–138 [Google Scholar]
  12. Samaan NA, Schultz PN, Haynie TP, Ordonez NG (1985) Pulmonary metastasis of differentiated thyroid carcinoma: treatment results in 101 patients. J Clin Endocrinol Metab 65:376–380 [DOI] [PubMed] [Google Scholar]
  13. Shimaoka K (1980) Adjunctive management of thyroid cancer: chemotherapy. J Surg Oncol 15:283–286 [DOI] [PubMed] [Google Scholar]
  14. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH, DeConti R (1985) A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56:2155–2160 [DOI] [PubMed] [Google Scholar]
  15. Tisell LE, Hansson G, Jansson S, Salander H (1986) Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 99:60–66 [PubMed] [Google Scholar]
  16. Williams SD, Birch R, Einhorn LH (1986) Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a southeastern cancer study group trial. Cancer Treat Rep 70:405–407 [PubMed] [Google Scholar]

Articles from Journal of Cancer Research and Clinical Oncology are provided here courtesy of Springer

RESOURCES